TickerTalks
Browse all tickers →
TickerTalks›$OTLK
OTOTLK

Outlook Therapeutics, Inc.

$OTLK·$40M·Biotechnology·Healthcare
$0.98-6.1%YTD+62.3%1Y-50.2%
Mentions · last 7 days
2026-07-25: 19 posts2026-07-26: 34 posts2026-07-27: 99 posts2026-07-28: 69 posts2026-07-29: 64 posts2026-07-30: 36 posts2026-07-31: 38 posts366+3%
Price updated 2d ago·X counts updated 2d ago
OTOTLK
$OTLKOutlook Therapeutics, Inc.
$0.98-6.10%366 posts+3%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $OTLK, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Comeback attemptWinding up for a moveAI verdict · as of 2026-07-31

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Outlook just got LYTENAVA FDA approval after four submission cycles — the FDA-first-and-only-ophthalmic-bevacizumab thesis has finally landed.

Outlook Therapeutics is a small-cap ophthalmic biotech whose entire equity value has depended on FDA approval of LYTENAVA (bevacizumab) for wet age-related macular degeneration. After four submission cycles, the approval finally landed on July 24.

  • The FDA approval is the primary catalyst: LYTENAVA is now the first and only FDA-approved ophthalmic bevacizumab (anti-VEGF) for wet AMD — a first-mover position in a market dominated by off-label compounding that comes with real legal exposure clinicians want to avoid.
  • The insider signal is positive: director Faisal Sukhtian bought roughly $100k on the open market at $1.05 on July 29 — a small dollar value but the kind of post-approval director buy that historically precedes a base rather than a fade.
  • The capital structure is being aggressively prepared: an S-3 shelf filed July 17 for future raises, plus shareholders approved increasing authorized shares from 260M to 600M — significant dilution capacity, but also ammunition to fund commercial launch or strategic alternatives.

The stock trades at $1.04 with a $57M market cap (a fraction of the FDA-approved anti-VEGF opportunity), and bulls compare the setup to LQDA's post-approval trajectory. What extends the move is early commercial-launch data on the Aug 13 print or any strategic-review disclosure; what breaks it is a dilutive equity raise announced before a partnership or a slow launch that questions the anti-VEGF economics.

Agrees with X sentimentX's bull frame — LYTENAVA FDA approval as first-and-only ophthalmic bevacizumab, LQDA-analog setup, director $100k buy, $170M market cap as still-undervalued relative to the anti-VEGF opportunity, and M&A optionality — is supported by the actual FDA action and the July 29 insider buy; the honest risk is the aggressive share-authorization expansion signaling likely dilution ahead.

What to watch: The Aug 13 Q2 print — LYTENAVA commercial launch metrics (prescription initiation, wholesaler stocking, gross-to-net expectations), and any strategic-review disclosure. Early commercial pull-through extends the move; a dilutive raise before a partnership or a slow launch resets the setup.

On the calendar: 2026-08-13 — Q2 2026 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment39 posts analyzed · as of 2026-08-01

Bulls dominate the Outlook Therapeutics thread after FDA approval of LYTENAVA for wet AMD, a BTIG upgrade to Buy with a $4 target, and an insider purchase of about $100K by director Sukhtian. The confusing element for holders: the stock fell 24% on approval, drawing 'makes no sense' reactions and comparisons to LQDA's post-approval dump-then-rip pattern. Earnings on Aug 13 is flagged as the next catalyst.

Read the AI verdict + X sentiment for $OTLK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing ONS-5010, a bevacizumab-based treatment for wet age-related macular degeneration and retinal diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $OTLK.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $OTLK

Neutral — Clinical-stage biotech developing ONS-5010, a bevacizumab-based treatment for wet age-related macular degeneration and retinal diseases; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.0%YTD
+40.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
54.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-182%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-72.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
193.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
178%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-361%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.9Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 15, 2026$-0.16$-0.12-33.3%
Q4 2025Feb 17, 2026$-0.22$-0.17-29.4%
Q3 2025Dec 19, 2025$-0.22$-0.26+15.4%
Q2 2025Aug 14, 2025$-0.44$-0.42-4.8%
Next earningsThu, Aug 13·consensus EPS $-0.09

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$127K—-17.2%-11007%$-0.05$-7.8M
Q1 FY26$-1.2M—102%1116%$-0.38$-14.9M
Q4 FY25$-92K-154.0%1099%18864%$-0.38$-12.4M
Q3 FY25$1.5M—70.8%-1046%$-0.55$-11.9M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$13.7M$7.2M – $25.9M-$0.48-$0.51 – -$0.421
FY27$58.0M$16.8M – $136.6M-$0.17-$0.26 – -$0.103
FY28$73.3M$38.8M – $139.2M$0.09$0.03 – $0.201
FY29$97.9M$51.9M – $185.8M$0.15$0.06 – $0.331
FY30$159.8M$84.7M – $303.4M$0.32$0.12 – $0.691

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.25%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-18.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+4.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 26.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today30.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.785-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyJul 29Sukhtian Faisal GhiathDirector95.4K sh$100KBuyJun 2Haddadin Yezan MuntherDirector29.0K sh$24KBuyMay 28Ghiath M. SukhtianDirector20.6M sh$12.0MBuyMay 27Sukhtian Faisal GhiathDirector122.2K sh$50KBuyMay 26Randy H ThurmanDirector5.0K sh$2KBuyMay 26Kurt J HilzingerDirector400.0K sh$177KBuyMay 26Haddadin Yezan MuntherDirector34.0K sh$15K
+ 3 other (2 awards · 1 expirelong) in window

See when $OTLK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJul 248-K — Item 5.02: Officer or director change
AI summary

Outlook Therapeutics, Inc. filed an 8-K on July 21, 2026 under Item 5.02, disclosing a departure or appointment of a director or officer. The body excerpt contains only the standard cover page. This is a routine leadership change at the ophthalmic biotech; the executive identity and role are in the attached exhibit. (A separate 8.01 filing was also made three days later — Job 32.)

S-3Shelf registrationJul 17S-3
AI summary

Outlook Therapeutics filed an S-3 shelf registration to register securities for future capital raises and is calling a special shareholder meeting to vote on increasing authorized shares from 260 million to 600 million and approving warrant exercises. The expanded share authorization is needed to support additional capital raises for the ophthalmology biopharmaceutical company.

8-KCharter amendmentJul 168-K — Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

Outlook Therapeutics held a special shareholder meeting to vote on proposals to increase authorized shares from 260 million to 600 million and approve warrant exercises. The vote on expanded share authorization provides the capital structure flexibility needed to support potential equity raises tied to the company's S-3 shelf registration.

8-KListing / delisting noticeJun 268-K — Item 3.01: Listing / delisting notice
AI summary

Outlook Therapeutics regained compliance with Nasdaq's minimum bid price requirement (closing price ≥$1.00 for 10 consecutive business days, June 11–25, 2026) and is no longer subject to Nasdaq delisting procedures. Relief news for this small ophthalmic biotech that had been under exchange compliance pressure; the stock must now sustain price levels to avoid re-entering the compliance process.

SC 13D/AActivist amendmentJun 1SC 13D/A
AI summary

A significant holder filed an amended Schedule 13D on Outlook Therapeutics, Inc. (OTLK) on June 1, 2026. Body unavailable — excerpt contains only the SEC cover-page header without filer name, updated stake, or amended intent.

424B5Prospectus supplement (offering)May 29424B5
AI summary

Outlook Therapeutics, Inc. (OTLK) filed a 424B5 prospectus supplement on May 29, 2026. Body unavailable — excerpt cuts off before the offering size, security type, price, or use of proceeds are disclosed.

424B5Prospectus supplement (offering)May 13424B5
AI summary

Outlook Therapeutics, Inc. (OTLK) filed a 424B5 prospectus supplement on May 13, 2026. Body unavailable — excerpt cuts off before the offering size, security type, price, or use of proceeds are disclosed.

8-KAgreement terminatedMay 138-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.02: Earnings release
AI summary

Outlook Therapeutics, Inc. (OTLK) filed a comprehensive 8-K on May 13, 2026 covering entry into a material definitive agreement (Item 1.01), termination of a material agreement (Item 1.02), and results of operations (Item 2.02). Body unavailable — excerpt cuts off before the specific agreement terms, terminated agreement details, and financial results are disclosed.

+ 32 other (11 routine 8-Ks · 5 8-Ks · 3 proxys · 3 424B5s) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needsseekingalpha.com·6d agoUS FDA approves Outlook Therapeutics' eye disease drugreuters.com·10d agoOutlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMDglobenewswire.com·10d agoOTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Reviewzacks.com·47d agoOutlook Therapeutics Eye Drug Review Returns To FDA For Fourth Timebenzinga.com·47d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$REPL$CAPR$IBRX$REGN$AURA$HALO$ALLO$MRNA
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport